CENTR(AR): Lungs Moving

Summary

Chronic Respiratory Diseases (CRDs) are associated with substantial morbidity and mortality, ranking as the third leading cause of death worldwide. Pulmonary rehabilitation (PR) is a fundamental evidence-based intervention for the management of a variety of CRDs, such as Chronic Obstructive Pulmonary Disease (COPD) and Interstitial Lung Diseases (ILDs). However, the benefits of PR tend to decline over time and there is currently no strong evidence that patients translate those benefits into a more active lifestyle. There is an urgent need for evidence-based interventions to promote physical activity (PA) participation, whilst maintaining PR positive effects in the long-term. Community-based PA interventions adjusted to the local context, as well as patients' needs and preferences, might be a key strategy to meet this target. CENTR(AR) will be a sustainable response to support healthy lifestyles and enhance long-term PR benefits, by providing access to PR within Primary Healthcare Centres (PHC), followed by the inclusion in a community-based PA program, which embraces urban facilities and available resources.

Conditions

• Chronic Respiratory Disease
• Lung Diseases
• Pulmonary Disease
• Chronic Obstructive Pulmonary Disease
• Interstitial Lung Disease

Interventions

OTHER

Community-based PA program

After completing the PR program, the experimental group (EG) will enroll in a 6-month personalized community-based PA program, which should be attended twice-weekly, minimum. During the first month the physiotherapist will guide patients through all available physical activities; afterwards, patients will be asked to choose one or two activities, according to their preference, which they'll attend for five more months. Physiotherapists' support will gradually decrease over time.

OTHER

Pulmonary Rehabilitation

Exercise training, twice a week, and education and psychosocial support once every other week during 12 weeks.

Sponsors & Collaborators

• Programa Operacional Inclusão Social e Emprego (POISE)

  collaborator UNKNOWN

• Programa Operacional Competitividade e Internacionalização (POCI) - Compete2020

  collaborator UNKNOWN

• Portuguese National Funding Agency for Science, Research and Technology (FCT)

  collaborator UNKNOWN

• Aveiro Institute of Biomedicine (iBiMED)

  collaborator UNKNOWN

• School of Health Sciences, University of Aveiro (ESSUA)

  collaborator UNKNOWN

• City Council/Municipality: a) Aveiro; b) Estarreja; c) Oliveira do Bairro; d) Montemor-o-Velho

  collaborator UNKNOWN

• Administração Regional de Saúde do Centro, IP (ARS Centro)

  collaborator UNKNOWN

• Centro Hospitalar do Baixo Vouga (CHBV), E.P.E.

  collaborator UNKNOWN

• Aveiro University

  lead OTHER

Principal Investigators

• Alda S. Marques, PhD · School of Health Sciences, University of Aveiro (ESSUA)

Study Design

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

SINGLE

Model

PARALLEL

Eligibility

Min Age

18 Years

Sex

ALL

Healthy Volunteers

No

Timeline & Regulatory

Start

2021-04-01

Primary Completion

2023-06-01

Completion

2023-12-31

Countries

• Portugal

Study Locations